

## LISTING OF CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A pharmaceutical composition comprising  
(i) a first specific binding agent, which is an F(ab')<sub>2</sub> or F(ab)<sub>2</sub> antibody fragment selected from an isolated antibody that specifically binds a target toxin or a large binding fragment of an antibody, wherein the large binding fragment that specifically binds the target toxin, and  
(ii) a second specific binding agent that comprises a small binding antibody fragment of an antibody wherein the small binding fragment that binds the target toxin, wherein the small binding fragment is selected from the group consisting of Fab, Fab', a single chain (sc) antibody, or FV, VH, or VK fragments.

Claims 2-6. (Cancelled)

7. (Currently amended) The composition of claim [[6]] 1 wherein the second specific binding agent is an Fab or Fab' fragment.

8. (Previously presented) The composition of claim 1 wherein the first and/or second binding agents are from polyclonal antibodies.

9. (Previously presented) The composition of claim 1 wherein the first and/or second binding agents are from monoclonal antibodies.

10. (Cancelled)

11. (Previously presented) The composition of claim 1 wherein the toxin is a Botulinum toxin.

12. (Previously presented) The composition of claim 11 wherein the first and second specific binding agents bind at least one of type A, B, C, D, E, F or G botulinum toxin.

13. (Previously presented) The composition of claim 12 wherein the composition comprises sets of first and second specific binding agents each set of specific binding agents binding a different one of botulinum toxins A, B, C, D, E, F or G.

14. (Previously presented) The composition of claim 1 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 90:10 to 10:90.

15. (Previously presented) The composition of claim 14 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 70:30 to 30:70.

16. (Previously presented) The composition of claim 15 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 60:40 to 40:60.

17. (Previously presented) The composition of claim 1 which further comprises a pharmaceutically acceptable carrier or excipient.

18. (Previously presented) The composition of claim 1 which is suitable for oral, parenteral, or intranasal administration, or for administration by inhalation or insufflation.

19. (Withdrawn) A method for treating the adverse effects of a toxin on a mammal comprising administering to a mammal in need thereof a composition comprising (i) a first specific binding agent selected from an isolated antibody that specifically binds a target toxin or a large binding fragment of an antibody wherein the large binding fragment specifically binds the target toxin, and (ii) a second specific binding agent that comprises a small binding fragment of an antibody wherein the small binding fragment binds the toxin.

20. (Cancelled)

21. (Withdrawn) A method of preventing the effects of a toxin on a mammal, said method comprising administering to a mammal in need thereof a composition comprising (i) a first specific binding agent selected from an isolated antibody that specifically binds a target toxin or a large binding fragment of an antibody wherein the large binding fragment specifically binds a target toxin, and (ii) a second specific binding agent that comprises a small binding fragment of an antibody wherein the small binding fragment binds the toxin.

22. (Cancelled)

23. (New) A pharmaceutical composition comprising (i) an antibody that specifically binds a Botulinum toxin and (ii) a small binding fragment of an antibody that specifically binds a Botulinum toxin selected from the group consisting of Fab, Fab', a single chain (sc) antibody, FV, VH, and VK fragments.

24. (New) The pharmaceutical composition of claim 23 wherein the antibody is IgG or IgT.